Virology & Mycology
Open Access

Effective protection induced by a monovalent DNA vaccine against dengue virus (DV) serotype 1 and a bivalent DNA vaccine against DV1 and DV2 in mice

Joint Event 10^th International Virology Summit & 4^th International Conference on Influenza & Zoonotic Diseases

July 02-04, 2018 | Vienna, Austria

Dongying Fan, Xiaoyan Zheng, Hui Chen, Ran Wang, Kaihao Feng, Na Gao and Jing An

Capital Medical University, China
Beijing Friendship Hospital, Capital Medical University, China
Beijing Institute for Brain Disorders, China

Posters & Accepted Abstracts: Virol Mycol

Abstract :

Dengue virus (DV) is the causal pathogen of dengue fever, which is one of the most rapidly spread mosquito-borne disease worldwide and has become a severe public health problem. Currently, there is no specific treatment; thus, a vaccine would be an effective countermeasure to reduce the morbidity and mortality. In this study, a DNA vaccine candidate pVAX1-D1ME expressing the DV1 prME protein was inoculated in BALB/c mice via intramuscular injection or electroporation, and the immunogenicity and protection were evaluated. Compared with traditional intramuscular injection, administration with 50 �¼g pVAX1-D1ME via electroporation with three immunizations induced persistent immune responses and effectively protection. In addition, immunization with a bivalent vaccine consisting of pVAX1-D1ME and pVAX1-D2ME via electroporation generated a balanced IgG response and neutralizing antibodies against DV1 and DV2 and could protect mice from lethal challenge with DV1 and DV2. This study sheds new light on developing a dengue tetravalent DNA vaccine.